PRODUCT INFORMATION

STAMARIL, powder and solvent for suspension for injection in multidose container
Yellow fever vaccine (Live)

ENGLISH TRANSLATION

<table>
<thead>
<tr>
<th>French MA dates</th>
<th>Modified sections in Annex I (as indicated in the ANSM document)</th>
</tr>
</thead>
<tbody>
<tr>
<td>27 July 2007</td>
<td>Full document</td>
</tr>
<tr>
<td>13 December 2010</td>
<td>Sections 4.4, 4.6, 6.5, 8</td>
</tr>
<tr>
<td>25 April 2013</td>
<td>Sections 2, 6.5, 8</td>
</tr>
</tbody>
</table>
ANNEX I

SUMMARY OF PRODUCT CHARACTERISTICS

1. NAME OF THE MEDICINAL PRODUCT
STAMARIL, powder and solvent for suspension for injection in multidose container
Yellow fever vaccine (Live)

2. QUALITATIVE AND QUANTITATIVE COMPOSITION
After reconstitution, 1 dose (0.5 ml) contains:
Yellow fever virus\(^1\) 17D-204 strain (live, attenuated) ............................................ not less than 1000 IU

\(^1\) Produced in specified pathogen-free chick embryos
For the full list of excipients, see Section 6.1.

3. PHARMACEUTICAL FORM
Powder and solvent for suspension for injection.
Before reconstitution, the powder is beige to orange beige; the solvent is clear and colourless.

4. CLINICAL PARTICULARS

4.1 Therapeutic indications
STAMARIL is indicated for active immunization against yellow fever in persons:
- travelling to, passing through or living in an endemic area,
- travelling to any country that requires an International Certificate of Vaccination for entry (which may or may not depend on the previous itinerary).
- handling potentially infectious materials (e.g. laboratory personnel).

See sections 4.2, 4.3 and 4.4 regarding the minimum age for vaccination of children under special circumstances and guidance for vaccination of other specific patient populations.

In order to comply with vaccine regulations and to be officially recognised, yellow fever vaccines must be administered in an approved World Health Organization (WHO) vaccination centre and registered on an International Certificate of Vaccination. This certificate is valid for 10 years from the 10th day after vaccination and immediately after re-vaccination.

4.2 Posology and method of administration

**Posology**

*Primary vaccination*

Adults and children aged 9 months and over: a single dose of 0.5 ml of reconstituted vaccine.

Children under 9 months of age: the vaccine must not be given to children less than 6 months old (see section 4.3). Vaccination against yellow fever is not usually recommended in children aged from 6 months up to 9 months except in specific circumstances and in accordance with available official recommendations (see section 4.4), in which case the dose is the same as in older children and adults.

The vaccine should be given at least 10 days before entering an endemic area since protective immunity may not be achieved until at least this time has elapsed.
Elderly
The dose is the same as for adults. However due to a higher risk of yellow fever vaccine-associated severe and potentially fatal disease in persons from 60 years of age, the vaccine should only be given when it is considered that there is a considerable and unavoidable risk of acquiring yellow fever infection (see sections 4.4 and 4.8).

Re-vaccination
Re-vaccination with one dose of 0.5 ml is recommended every 10 years in persons considered to be at risk of exposure.

International health regulations require re-vaccination, using the same dose as for primary vaccination, at intervals of 10 years in order to retain a valid certificate.

Method of administration
It is preferable that the vaccine is injected by the subcutaneous route.

Intramuscular injection may be performed if this is in accordance with applicable official recommendations.

For intramuscular use the recommended injection sites are the anterolateral aspect of the thigh in the infants and toddlers (6 months up to 2 years of age) and the deltoid muscle in older children and adults.

DO NOT INJECT INTRAVASCULARLY.

See section 6.6. for instructions on reconstitution.

4.3 Contraindications
• Hypersensitivity reaction to eggs, chicken proteins or to any component of STAMARIL.
• Serious hypersensitivity reactions (e.g., anaphylaxis) after a previous dose of any yellow fever vaccine.
• Immunosuppression, whether congenital, idiopathic or as a result of treatment with systemic steroids (greater than the standard dose of topical or inhaled steroids), radiotherapy or cytotoxic drugs.
• History of thymus dysfunction (including thymoma, thymectomy).
• Symptomatic HIV infection.
• Asymptomatic HIV infection when accompanied by evidence of impaired immune function (see section 4.4).
• Age less than 6 months (see sections 4.2 and 4.4).
• Current severe febrile illness.

4.4 Special warnings and precautions for use
As with all injectable vaccines, appropriate medical treatment and supervision should always be readily available in case of anaphylaxis or other severe hypersensitivity reaction following administration of the vaccine.

STAMARIL should be administered only to persons who are/will be at risk of infection with yellow fever virus or who must be vaccinated to comply with international health regulations. Before considering administration of yellow fever vaccine, care should be taken to identify those who might be at increased risk of adverse reactions following vaccination (see section 4.3 and below).

Yellow fever vaccine-associated neurotropic disease (YEL-AND)
Very rarely, yellow fever vaccine-associated neurotropic disease (YEL-AND) has been reported following vaccination, with sequelae or with fatal outcome in some cases (see section 4.8). Clinical features have appeared within one month of vaccination and include high fever with headache that may progress to include one or more of the following: confusion, encephalitis/encephalopathy, meningitis, focal neurological deficits, or Guillain Barré syndrome. To date, those affected have been primary vaccinees. The risk appears to be higher in those aged over 60 years, although cases have been also reported in younger persons or following transmission from nursing mothers to the infants.

Yellow fever vaccine-associated viscerotropic disease (YEL-AVD)
Very rarely, yellow fever vaccine-associated viscerotropic disease (YEL-AVD) resembling fulminant infection by wild-type virus has been reported following vaccination (see section 4.8). The clinical
presentation may include fever, fatigue, myalgia, headache, hypotension, progressing to one or more of metabolic acidosis, muscle and liver cytolysis, lymphocytopenia and thrombocytopenia, renal failure and respiratory failure. The mortality rate has been around 60%. To date, all cases of YEL-AVD have been in primary vaccinees with onset within 10 days of vaccination. The risk appears to be higher in those aged over 60 years although cases have also been reported in younger persons. Disease of the thymus gland has also been recognised as a potential risk factor (see section 4.3 and 4.8).

**Immunosuppressed persons**

STAMARIL must not be administered to immunosuppressed persons (see section 4.3).

If the immunosuppression is temporary, vaccination should be delayed until the immune function has recovered. In patients who have received systemic corticosteroids for 14 days or more, it is advisable to delay vaccination until at least one month after completing the course.

**HIV infection**

STAMARIL must not be administered to persons with symptomatic HIV infection or with asymptomatic HIV infection when accompanied by evidence of impaired immune function (see section 4.3). However, there are insufficient data at present to determine the immunological parameters that might differentiate persons who could be safely vaccinated and who might mount a protective immune response from those in whom vaccination could be both hazardous and ineffective. Therefore, if an asymptomatic HIV-infected person cannot avoid travel to an endemic area, available official guidance should be taken into account when considering the potential risks and benefits of vaccination.

**Children born to HIV positive mothers**

Children aged at least 6 months (see sections 4.2 and 4.3 and below) may be vaccinated if it is confirmed that they are not infected with HIV.

HIV infected children aged at least 6 months who are potentially in need of protection against yellow fever should be referred to a specialist paediatric team for advice on whether or not to vaccinate.

**Age**

**Children aged 6 to 9 months**

STAMARIL must not be administered to children before the age of 6 months (see section 4.3). Children aged from 6 months up to 9 months should only be vaccinated under special circumstances (e.g. during major outbreaks) and on the basis of current official advice.

**Persons aged 60 years and older**

Some serious and potentially fatal adverse reactions (including systemic and neurological reactions persisting more than 48 hours, YEL-AVD and YEL-AND) appear to occur at higher frequencies after the age of 60 years. Therefore, the vaccine should only be given to those who have a considerable risk of acquiring yellow fever (see above and section 4.8).

Because intramuscular injection can cause injection site haematoma, STAMARIL should not be given by the intramuscular route to persons with any bleeding disorder, such as haemophilia or thrombocytopenia, or to persons on anticoagulant therapy. The subcutaneous route of administration should be used instead.

Patients with rare hereditary problems of fructose intolerance should not take this vaccine.

**Transmission**

There are very few reports suggesting that transmission of yellow fever vaccine virus may occur from nursing mothers, who received yellow fever vaccine postpartum, to the infant. Following transmission the infants may develop yellow fever vaccine-associated neurotropic disease (YEL-AND) from which the infants recover (see section 4.6).

**4.5 Interaction with other medicinal products and other forms of interaction**

STAMARIL must not be mixed with any other vaccine or medicinal product in the same syringe.

If there is a need to administer another injectable vaccine(s) at the same time as STAMARIL each vaccine should be injected into a separate site (and preferably a separate limb).

STAMARIL may be administered at the same time as measles vaccine if this is in accordance with official recommendations.
STAMARIL may be administered at the same time as vaccines containing typhoid Vi capsular polysaccharide and/or inactivated hepatitis A virus.

STAMARIL must not be administered to persons who are receiving immunosuppressant therapy (e.g., cytotoxic agents, systemic steroids, greater than standard dose of topical or inhaled steroids or other agents). See section 4.3.

4.6 Pregnancy and lactation

Pregnancy

No animal reproduction studies have been conducted with STAMARIL and the potential risk for humans is unknown. Data on a limited number of exposed pregnancies indicate no adverse effects of STAMARIL on pregnancy or the health of the fetus/newborn child. Nevertheless, STAMARIL should be given to pregnant women only when clearly needed and only after careful consideration of the potential risks and benefits.

Lactation

As there is a probable risk of transmission of the vaccine virus strain to the infants from breast-feeding mothers, STAMARIL should not be given to nursing mothers unless when clearly needed such as during an outbreak control, and following an assessment of the risks and benefits (see section 4.4).

4.7 Effects on ability to drive and use machines

No studies on the effects on the ability to drive or use machines have been performed.

4.8 Undesirable effects

Data from clinical studies

Across clinical studies, the most common adverse reactions occurring after vaccine administration were local reactions, reported in approximately 16% of subjects.

The following adverse events are from one clinical study in which 106 healthy adult subjects received STAMARIL.

The adverse events are ranked under headings of frequency, using the following convention:

- Very common: \( \geq 1/10 \)
- Common: \( \geq 1/100 \) and < 1/10
- Uncommon: \( \geq 1/1000 \) and < 1/100

Nervous system disorders

Very common: headache.

Gastro-intestinal system disorders

Common: nausea, diarrhoea, vomiting.
Uncommon: abdominal pain.

Musculo-skeletal and connective tissue disorders

Common: myalgia.
Uncommon: arthralgia.

General disorders and administration site conditions

Very common: local reactions (including pain, redness, haematoma, induration, swelling).
Common: pyrexia, asthenia.

Data from post-marketing experience

The following additional adverse events have been reported during post marketing experience with STAMARIL. They are based on spontaneous reporting therefore the frequencies are unknown.

Blood and lymphatic system disorders

Lymphadenopathy.

Immune system disorders

Anaphylaxis, angioedema.
**Nervous system disorders**
Cases of neurotropic disease (known as YEL-AND), some of which have had a fatal outcome, have been reported following yellow fever vaccination (see section 4.4). YEL-AND may manifest as high fever with headache that may progress to include one or more of confusion, lethargy, encephalitis, encephalopathy and meningitis (see section 4.4). Other neurological signs and symptoms have been reported and include convulsion, Guillain-Barré syndrome and focal neurological deficits.

**Skin and subcutaneous tissue disorders**
Rash, urticaria.

**General disorders and administration site conditions**
Rash, urticaria.

**Skin and subcutaneous tissue disorders**
Rash, urticaria.

**General disorders and administration site conditions**
Rash, urticaria.

**Nervous system disorders**
Cases of neurotropic disease (known as YEL-AND), some of which have had a fatal outcome, have been reported following yellow fever vaccination (see section 4.4). YEL-AND may manifest as high fever with headache that may progress to include one or more of confusion, lethargy, encephalitis, encephalopathy and meningitis (see section 4.4). Other neurological signs and symptoms have been reported and include convulsion, Guillain-Barré syndrome and focal neurological deficits.

**Skin and subcutaneous tissue disorders**
Rash, urticaria.

**General disorders and administration site conditions**
Rash, urticaria.

**Additionl information on special population**
Congenital or acquired immunodeficiency has been identified as a risk factor for neurotropic disease (see sections 4.3 and 4.4). Age of more than 60 years (see section 4.4) has been identified as a risk factor for YEL-AVD and YEL-AND. A medical history of thymic disease (see sections 4.3 and 4.4) has been identified as a risk factor for YEL-AVD.

**4.9 Overdose**
No case of overdose has been reported.

**5. PHARMACOLOGICAL PROPERTIES**

**5.1 Pharmacodynamic properties**

Pharmacotherapeutic group: Yellow fever vaccine (live), ATC code: J07B-L1.

STAMARIL is a live attenuated yellow fever virus vaccine. As with other live attenuated viral vaccines, there is a sub-clinical infection in healthy recipients that results in the production of specific B and T cells and the appearance of specific circulating antibody.

Protective immunity appears from about 10 days after injection. Although international health regulations require re-vaccination at intervals of 10 years in order to retain a valid certificate, some degree of immunity likely persists for more than 10 years.

**5.2 Pharmacokinetic properties**

No pharmacokinetic studies have been performed.

**5.3 Preclinical safety data**

Pre-clinical data reveal no special hazard for humans.

**6. PHARMACEUTICAL PARTICULARS**

**6.1 List of excipients**

**Powder:**

- Lactose
- Sorbitol E420
- L-histidine hydrochloride
- L-alanine
- Sodium chloride
- Potassium chloride
Disodium phosphate
Monopotassium phosphate
Calcium chloride
Magnesium sulphate

**Solvent:**
Sodium chloride
Water for injections

6.2 **Incompatibilities**
This vaccine must not be mixed with other medicinal products.

6.3 **Shelf life**
3 years.
After reconstitution, the product must be kept in a refrigerator (2°C - 8°C) and must be used within 6 hours.

6.4 **Special precautions for storage**
Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vial in the outer carton in order to protect from light.
For storage conditions of the reconstituted medicinal product, see section 6.3.

6.5 **Nature and contents of container**
Powder (10 doses) in vial (type I glass) with a stopper (bromobutyl) + 5 ml of solvent in vial (type I glass) with a stopper (chlorobutyl) – Pack size of 10.
Powder (10 doses) in vial (type I glass) with a stopper (bromobutyl) + 5 ml of solvent in ampoule (polypropylene) – Pack size of 10.

6.6 **Special precautions for disposal and other handling**
The powder is reconstituted in its container with a small quantity of sodium chloride 9 mg/ml (0.9%) solution for injection.
The vial is shaken and after dissolution, the suspension obtained is withdrawn and added to the remaining solution. Before administration, the reconstituted vaccine is vigorously shaken.
For each vaccination 0.5 ml is withdrawn.
The reconstitution and withdrawal of vaccine should be performed under aseptic conditions.
After reconstitution, STAMARIL is a beige to pink beige suspension for injection.
Contact with disinfectants is to be avoided since they may inactivate the virus.
Any unused product or waste material should be disposed of, preferably by heat inactivation or incineration, in accordance with local requirements.

7. **MARKETING AUTHORISATION HOLDER**
SANOFI PASTEUR
2 AVENUE PONT PASTEUR
69007 LYON
FRANCE

8. **MARKETING AUTHORISATION NUMBER(S)**
- 361 221-2 or 34009 361 221 2 3: Powder for suspension for injection in vial (type I glass) with a stopper (bromobutyl) + 5 ml of solvent in vial (type I glass) with a stopper (chlorobutyl) – Pack size of 10.
• 498 061-0 or 34009 498 061 0 2: Powder for suspension for injection in vial (type I glass) with a stopper (bromobutyl) + 5 ml of solvent in ampoule (polypropylene) – Pack size of 10.

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

• Date of first authorisation: 19 July 1979
• Date of renewal of the authorisation: 26 June 2005

10. DATE OF REVISION OF THE TEXT

25 April 2013

11. DOSIMETRY

Not applicable.

12. INSTRUCTIONS FOR PREPARATION OF RADIOPHARMACEUTICALS

Not applicable.

GENERAL CLASSIFICATION FOR SUPPLY

Reserved for vaccination centres authorised to perform yellow fever vaccination.
ANNEX II

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE

A.1. Name and address of the manufacturer(s) of the biological active substance(s)

SANOFI PASTEUR
PARC INDUSTRIEL D’INCARVILLE
B.P. 101
27101 VAL DE REUIL CEDEX
FRANCE

A.2. Name and address of the manufacturer(s) responsible for batch release

SANOFI PASTEUR
2, AVENUE PONT PASTEUR
69007 LYON
FRANCE

B. CONDITIONS OF THE MARKETING AUTHORISATION

B.1. Conditions or restrictions regarding supply and use imposed on the marketing authorisation holder

Reserved for vaccination centres authorised to perform yellow fever vaccination.

B.2. Conditions or restrictions with regard to the safe and effective use of the medicinal product

Not applicable.

B.3. Other conditions

Not applicable.

C. SPECIFIC OBLIGATIONS TO BE FULFILLED BY THE MARKETING AUTHORITY HOLDER

Not applicable.

D. QUALITATIVE AND QUANTITATIVE COMPOSITION IN EXCIPIENTS

One dose (0.5 ml) of freeze-dried vaccine contains:

Lactose .............................................................................................................................................. 2 mg
Sorbitol E420 ..................................................................................................................................... 1 mg
Chlorhydrate of L-histidine ....................................................................................................... 0.1045 mg
L-alanine ................................................................................................................................... 0.0455 mg
Sodium chloride .......................................................................................................................... 0.275 mg
Potassium chloride ..................................................................................................................... 0.007 mg
Disodium phosphate ................................................................................................................... 0.037 mg
Monopotassium phosphate ........................................................................................................ 0.008 mg
Calcium chloride ........................................................................................................................ 0.005 mg
Magnesium sulphate .................................................................................................................. 0.004 mg

One dose (0.5 ml) of reconstitution solvent contains:

Sodium chloride .............................................................................................................................. 4.5 mg
Water for injections .................................................................................................................... q.s. 0.5 ml
## ANNEX IIIA

### LABELLING

**PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING**

<table>
<thead>
<tr>
<th>NATURE/TYPE</th>
<th>Outer packaging or immediate packaging</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Vials</td>
</tr>
</tbody>
</table>

#### 1. NAME OF THE MEDICINAL PRODUCT

**STAMARIL**, powder and solvent for suspension for injection in multidose container

Yellow fever vaccine (Live)

#### 2. STATEMENT OF ACTIVE SUBSTANCES

After reconstitution, 1 dose (0.5 ml) contains:

- Yellow fever virus\(^1\) 17D-204 strain (live, attenuated) \(\ldots\) not less than 1000 IU

\(^1\) Produced in specified pathogen-free chick embryos

#### 3. LIST OF EXCIPIENTS

**Powder**: lactose, sorbitol, L-histidine hydrochloride, L-alanine, sodium chloride, potassium chloride, disodium phosphate, monopotassium phosphate, calcium chloride, magnesium sulphate.

**Solvent**: sodium chloride (0.9%), water for injections.

#### 4. PHARMACEUTICAL FORM AND CONTENTS

Powder and solvent for suspension for injection.

This packaging contains 10 multidose vials of powder + 10 multidose <vials> <ampoules> of solvent.

#### 5. METHOD AND ROUTE(S) OF ADMINISTRATION

Subcutaneous or intramuscular use.

Read the package leaflet before use.

#### 6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE REACH AND SIGHT OF CHILDREN

Keep out of the reach and sight of children.

#### 7. OTHER SPECIAL WARNING(S), IF NECESSARY

Not applicable.
8. **EXPIRY DATE**

EXP {MM/AAAA}

9. **SPECIAL STORAGE CONDITIONS**

Store in a refrigerator (2°C – 8°C). Do not freeze. Keep the vial of powder and <the vial> <the ampoule> of solvent in the outer carton in order to protect from light.

10. **SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF APPROPRIATE**

Not applicable.

11. **NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

**Holder**
SANOFI PASTEUR
2, AVENUE PONT PASTEUR
69007 LYON
FRANCE

**Distributor**
SANOFI PASTEUR MSD SNC
8, RUE JONAS SALK
69007 LYON
FRANCE

**Manufacturer**
SANOFI PASTEUR
2, AVENUE PONT PASTEUR
69007 LYON
FRANCE

12. **MARKETING AUTHORISATION NUMBER(S)**

Number of Authorized Medicinal Product:

13. **BATCH NUMBER**

Batch {number}

14. **GENERAL CLASSIFICATION FOR SUPPLY**

Reserved for vaccination centres authorised to perform yellow fever vaccination.

15. **INSTRUCTIONS ON USE**

Not applicable.

16. **INFORMATION IN BRAILLE**

Not applicable.

PICTOGRAM TO APPEAR ON THE OUTER PACKAGING OR, WHERE THERE IS NO OUTER PACKAGING, ON THE IMMEDIATE PACKAGING

Not applicable.
## Minimum Particulars to Appear on Blisters or Strips

### Nature/Type

<table>
<thead>
<tr>
<th>Blisters / Strips</th>
</tr>
</thead>
<tbody>
<tr>
<td>Not applicable.</td>
</tr>
</tbody>
</table>

### 1. Name of the Medicinal Product

Not applicable.

### 2. Name of the Marketing Authorisation Holder

- **Holder**
  - Not applicable.
- **Distributor**
  - Not applicable.

### 3. Expiry Date

Not applicable.

### 4. Batch Number

Not applicable.

### 5. Other

Not applicable.
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

NATURE/TYPEx Small immediate packaging units
<Vials> <Ampoules>

1. NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION
STAMARIL, powder and solvent for suspension for injection in multidose container
Yellow fever vaccine (Live)

2. METHOD OF ADMINISTRATION
Powder in vial: SC or IM route.
<Vial> <Ampoule> of solvent: not applicable.

3. EXPIRY DATE
EXP {MM/AAAA}

4. BATCH NUMBER
Batch {number}

5. CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT
Powder in vial: 10 doses.
<Vial> <Ampoule> of solvent: 10 doses of 0.9% sodium chloride solution for injection.

6. OTHER
Not applicable.
STAMARIL, powder and solvent for suspension for injection in multidose container
Yellow fever vaccine (Live)

Read all of this leaflet carefully before you/your child are vaccinated.
- Keep this leaflet. You may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This vaccine has been prescribed for you. Do not pass it on to others.
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

1. WHAT STAMARIL IS AND WHAT IT IS USED FOR

Pharmacotherapeutic group
Not applicable.

Therapeutic indications
STAMARIL is a vaccine that provides protection against a serious infectious disease called yellow fever. Yellow fever occurs in certain areas of the world and is spread to man through the bites of infected mosquitoes.

STAMARIL is given to people who:
- are travelling to, passing through or living in an area where yellow fever occurs,
- are travelling to any country that requires an International Certificate of Vaccination for entry, this may depend on the countries previously visited during the same trip,
- may handle infectious materials such as laboratory workers.

To obtain a vaccination certificate against yellow fever it is necessary to be vaccinated in an approved vaccination centre so that an International Certificate of Vaccination can be issued. This certificate is valid from the 10th day and until 10 years after the first dose of vaccine.

Certificates issued after a booster vaccination (see section 3 below) are valid immediately after the injection.

2. BEFORE YOU USE STAMARIL

List of information necessary before taking the medicinal product
It is important to tell your doctor or nurse if any of the points below apply to the person receiving the vaccine. If there is anything you do not understand, ask your doctor or nurse to explain.
Contraindications

STAMARIL should not be given if you or your child:

- are allergic to eggs, chicken proteins or any other ingredient of STAMARIL, or have experienced a serious reaction after an injection of a yellow fever vaccine,
- have a poor or weakened immune system for any reason, such as illness or medical treatments (for example corticoids or chemotherapy),
- have a weakened immune system due to HIV infection. Your doctor will tell you if you can still receive STAMARIL based on your blood tests,
- are infected with HIV and have active symptoms due to the infection,
- have a history of problems with your thymus gland or have had your thymus gland removed for any reason,
- have an illness with a fever or acute infection. The vaccination will be postponed until you have recovered,
- are less than 6 months old.

Precautions for use; special warnings

Take special care with STAMARIL if:

- you are over 60 years old as you have an increased risk of certain types of severe but rare reactions to yellow fever vaccines (including serious reactions that affect the brain and nerves, as well as vital organs, see section 4). You will only be given the vaccine if the risk of infection with the virus is well established in countries where you are going to stay,
- your child is aged 6 to 9 months. STAMARIL may be given to children aged between 6 and 9 months only in special situations and on the basis of current official recommendations,
- you are infected with the HIV but do not present with any HIV infection related symptoms, your doctor will specify whether STAMARIL can be given based on your blood tests,
- your child is infected with the HIV (AIDS). The doctor may need to perform specific exams and seek advice from a specialist before telling you whether your child may receive STAMARIL,
- you have bleeding disorders (such as haemophilia or a low level of platelets) or are taking medicines that reduce blood circulation. You can still receive STAMARIL provided that it is injected under the skin and not into a muscle (see section 3).

Interactions with other medicinal products

Taking other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription.

If you have recently been receiving any treatment which may have weakened your immune system, vaccination against yellow fever should be postponed until your laboratory results show that your immune system has recovered. Your doctor will advise you when it is safe for you to be vaccinated.

STAMARIL can be given at the same time as a measles vaccine or vaccines against typhoid (those containing the Vi capsular polysaccharide) and/or hepatitis A vaccines.

Interactions with food and drink

Not applicable.

Interaction with phytotherapy or alternative therapy products

Not applicable.

Use during pregnancy and breast-feeding

Pregnancy and breastfeeding

Tell your doctor or nurse if you are pregnant, think you might be pregnant or are breastfeeding. You should not receive STAMARIL unless this cannot be avoided. Your doctor or nurse can advise you on whether it is essential that you are vaccinated while pregnant or breastfeeding.
3. HOW TO USE STAMARIL

Instructions for proper use

STAMARIL is given as an injection by a doctor or nurse.

It is usually injected just underneath the skin but it can be given into a muscle if that is in the applicable official recommendation for the country in which you live.

It must not be injected into a blood vessel.

Dosage, Method and/or route(s) of administration, Frequency of administration and Duration of treatment

Posology

STAMARIL is given as a single, 0.5 millilitre dose to adults and children from 6 months of age. The first dose should be given at least 10 days before being at risk of infection with yellow fever, because it takes 10 days for the first dose of vaccine to work and provide good protection against the yellow fever virus. The protection provided by this dose will last 10 years.

A booster dose (0.5 millilitre) is recommended every 10 years if you are still thought to be at risk of infection with yellow fever (e.g. you still travel to or are living in areas where yellow fever can be caught or could be infected through your work).

If you have any further questions on the use of this vaccine, ask your doctor.

Symptoms and instructions in the case of overdose

Not applicable.

Instructions in the case of missing doses

Not applicable.

Risk of withdrawal syndrome

Not applicable.

4. POSSIBLE SIDE EFFECTS

Description of side effects

Like all medicines, STAMARIL can cause side effects, although not everybody gets them.

Serious side effects

The following serious side effects have sometimes been reported:

Allergic reactions

- Rash, itching or hives on the skin.
• Swelling of the face, lips, tongue or other parts of the body.
• Difficulty swallowing or breathing.
• Loss of consciousness.

Reactions affecting the brain and nerves
These may occur within one month of the vaccination and have sometimes been fatal.

Symptoms include:
• High fever with headache and confusion.
• Extreme tiredness.
• Stiff neck.
• Inflammation of brain and nerve tissues.
• Fits.
• Loss of movement or feeling affecting certain parts or all of the body.

Serious reaction affecting vital organs
This may occur within 10 days of the vaccination and may have a fatal outcome. The reaction can resemble an infection with the yellow fever virus. It generally begins with feeling tired, fever, headache, muscle pain and sometimes low blood pressure. It may then go on to a severe muscle and liver disorders, drops in number of some types of blood cells resulting in unusual bruising or bleeding and increased risk of infections, and loss of normal functioning of the kidneys and lungs.

If you experience ANY of the above symptoms contact your doctor IMMEDIATELY.

Other side effects
Very common side effects (reported by more than 1 in 10 people)
Problems around the injection site (such as redness, bruising, pain or discomfort, swelling or appearance of a hard lump) and headache.

Common side effects (reported by less than 1 in 10 people)
Feeling or being sick, diarrhoea, muscle pains, fever and weakness.

Uncommon side effects (reported by less than 1 in 100 people)
Painful joints and stomach pains.

Other side effects include:
Swollen glands.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. HOW TO STORE STAMARIL

Keep out of the reach and sight of children.

**Expiry date**

Do not use STAMARIL after the expiry date which is stated on the carton. The expiry date refers to the last day of that month.

**Storage conditions**

Store in a refrigerator between 2°C and 8°C. Do not freeze.
Keep the vial of powder and the vial or ampoule of solvent in the outer carton in order to protect from light.
After reconstitution, the vaccine must be used within 6 hours.

**Where appropriate, warning against certain visible signs of deterioration**

Not applicable.
6. FURTHER INFORMATION

<table>
<thead>
<tr>
<th>Full statement of the active substances and excipients</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>What Stamaril contains?</strong></td>
</tr>
<tr>
<td>The active substance of the vaccine is strain 17D-204 of the yellow fever virus (produced in embryonated chicken eggs). The live virus has been weakened so that the healthy persons vaccinated do not develop yellow fever. Each 0.5 ml-dose contains no less than 1000 International Units of the live attenuated virus.</td>
</tr>
<tr>
<td><strong>The other ingredients are:</strong></td>
</tr>
<tr>
<td>Powder: lactose, sorbitol, L-histidine hydrochloride, L-alanine, sodium chloride, potassium chloride, disodium phosphate, monopotassium phosphate, calcium chloride, magnesium sulphate.</td>
</tr>
<tr>
<td>Solvent: sodium chloride and water for injections.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Pharmaceutical form and contents</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>What STAMARIL looks like and contents of the pack</strong></td>
</tr>
<tr>
<td>The vaccine is a powder for suspension for injection contained in a 10 dose vial. Before use, the beige to orange-beige powder is mixed with the sodium chloride solution provided in the other vial or in the ampoule, giving a beige to pink-beige suspension.</td>
</tr>
<tr>
<td>STAMARIL is available in pack sizes of 10.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name and address of the marketing authorisation holder and of the manufacturing authorisation holder responsible for batch release, if different</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Holder</strong></td>
</tr>
<tr>
<td>SANOFI PASTEUR [2, AVENUE PONT PASTEUR 69007 LYON FRANCE]</td>
</tr>
<tr>
<td><strong>Distributor</strong></td>
</tr>
<tr>
<td>SANOFI PASTEUR MSD SNC [8, RUE JONAS SALK 69007 LYON FRANCE]</td>
</tr>
<tr>
<td><strong>Manufacturer</strong></td>
</tr>
<tr>
<td>SANOFI PASTEUR [2, AVENUE PONT PASTEUR 69007 LYON FRANCE]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Names of the medicinal product in the Member States of the European Economic Area</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>This medicinal product is authorised in the Member States of the EEA under the following names:</td>
<td></td>
</tr>
<tr>
<td>Austria STAMARIL</td>
<td></td>
</tr>
<tr>
<td>Belgium STAMARIL Pasteur</td>
<td></td>
</tr>
<tr>
<td>Czech Republic STAMARIL Pasteur</td>
<td></td>
</tr>
<tr>
<td>Denmark STAMARIL</td>
<td></td>
</tr>
<tr>
<td>Estonia STAMARIL</td>
<td></td>
</tr>
<tr>
<td>Finland STAMARIL</td>
<td></td>
</tr>
<tr>
<td>France STAMARIL</td>
<td></td>
</tr>
</tbody>
</table>
Date of approval of the package leaflet

This leaflet was last approved in 04/2013.

Marketing authorisation under exceptional circumstances

Not applicable.

Internet information

Detailed information on this medicinal product is available on the internet site of ANSM (France): www.ansm.sante.fr.

Information intended for healthcare professionals

The following information is directed exclusively to health professionals:

The powder is reconstituted in its container with a small quantity of sodium chloride 9 mg/ml (0.9%) solution for injection.

The vial is shaken and after dissolution, the suspension obtained is withdrawn and added to the remaining solution. Before administration, the reconstituted vaccine is vigorously shaken.

For each vaccination 0.5 ml is withdrawn.

The reconstitution and withdrawal of vaccine should be performed under aseptic conditions.

After reconstitution STAMARIL is a beige to pink beige suspension for injection.

Contact with disinfectants is to be avoided since they may inactivate the virus.

Any unused product or waste material should be disposed of, preferably by heat inactivation or incineration, in accordance with local requirements.

Other

Not applicable.